Usted buscó: prenatal developmentlive litter size (Inglés - Maltés)

embryo toxicity (increased resorptions) and reduced litter size was also observed.
kienet osservata wkoll tossiċità tal-embriju (żieda fir- riassorbimenti) u tnaqqis fid-daqs tal-boton.

however, fetal resorption and reduced litter size occurred in pregnant rabbits administered daily doses of 3 to 100 µg/kg.
madankollu, fil-fniek tqal kien hemm assorbiment tal-fetu u tnaqqis fl-ammont ta’ frieħ meta ngħataw dożi ta’ 3 sa 100 µg/kg kuljum.

in embryofoetal development studies, dasatinib likewise induced embryolethality with associated decreases in litter size in rats, as well as foetal skeletal alterations in both rats and rabbits.
fi studji dwar l-iżvilupp embrijofetali, dasatinib, bl-istess mod, wassal għal embrijoletalità bi tnaqqis fid-daqs tal-boton fil-firien, kif ukoll għal tibdil skeletrali tal-fetu kemm fil-firien kif ukoll fil-fniek.

when given during the preimplantation period, raloxifene delayed and disrupted embryo implantation resulting in prolonged gestation and reduced litter size but development of offspring to weaning was not affected.
meta ngħata fil-perijodu ta’ qabel il-bajda iffertiliżżata teħel mal-ħajt tal-ġuf, raloxifene ittardja u ħarbat il-proċess ta’ twaħħil ta’ l-embriju li rriżulta f’perijodu itwal ta’ tqala u tnaqqis fid-daqs tal-boton, iżda m’effetwax l-iżvilupp ta’ l-annimal mit-twelid sa kemm infatam.

at exposures lower than those obtained at therapeutic doses in humans, posaconazole caused skeletal variations and malformations, dystocia, increased length of gestation, reduced mean litter size and postnatal viability.
b’esponiment aktar baxxi minn dawk li jinkisbu b’dożi terapewtiċi fil-bnedmin, posaconazole ikkawża bidliet skeletrali u malformazzjonijiet, distoċja, żmien ta’ ġestazzjoni itwal, tnaqqis fil-medja tad-daqs tal-botom u tas- soppravivenza ta’ wara t-twelid.

in reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure.
f’studji dwar l-effett tossiku fuq ir-riproduzzjoni u l-iżvillup f’ annimali gerriema u ġrieden, ma kienux osservati effetti teratoġeniċi imma kien hemm żieda fin-numru ta’ frieħ li twieldu mejta u mwiet ta’ frieħ fil-perjodu ta’ wara t-twelid u tnaqqis żgħir ħafna fid-daqs tal-boton u fil-piz tal-frieħ b’dożi tossiċi fl-omm fil-firien li jikkorrespondu għal livelli ta’ esponiment sistemiċi simili għal esponiment kliniku mistenni.

at doses of 0.1 to 10 mg/kg/day in female rats, raloxifene disrupted estrous cycles of female rats during treatment, but did not delay fertile matings after treatment termination and only marginally reduced litter size, increased gestation length, and altered the timing of events in neonatal development.
f’dożi ta’ 0.1 sa 10 mg/kg/jum fil-firien ta’ sess femminil, raloxifene fixkel iċ-ċiklu estrous fil-firien ta’ sess femminil waqt il-kura, iżda ma ttardjax it-tgħammir fertili wara li twaqqaf il-kura, u naqqas bi ftit biss id-daqs tal-boton, żied it-tul ta’ żmien tat-tqala, u biddel iż-żmien fl-avvenimenti ta’ l-iżvilupp tal-wild.